MoonLake Immunotherapeutics
MLTX
$39.65
$0.982.53%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 9.22M | 7.38M | 6.92M | 6.81M | 6.93M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 49.58M | 43.11M | 30.58M | 19.82M | 15.03M |
| Operating Income | -49.58M | -43.11M | -30.58M | -19.82M | -15.03M |
| Income Before Tax | -46.35M | -36.02M | -24.68M | -13.91M | -7.84M |
| Income Tax Expenses | 41.10K | 92.10K | 78.70K | 70.30K | 44.30K |
| Earnings from Continuing Operations | -46.40M | -36.11M | -24.76M | -13.98M | -7.89M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 791.20K | 724.10K | 491.70K | 301.90K | 450.30K |
| Net Income | -45.60M | -35.39M | -24.27M | -13.67M | -7.44M |
| EBIT | -49.58M | -43.11M | -30.58M | -19.82M | -15.03M |
| EBITDA | -48.28M | -43.08M | -30.55M | -19.80M | -14.67M |
| EPS Basic | -0.72 | -0.56 | -0.39 | -0.22 | -0.12 |
| Normalized Basic EPS | -0.45 | -0.35 | -0.24 | -0.13 | -0.07 |
| EPS Diluted | -0.72 | -0.56 | -0.39 | -0.22 | -0.12 |
| Normalized Diluted EPS | -0.45 | -0.35 | -0.24 | -0.13 | -0.07 |
| Average Basic Shares Outstanding | 63.07M | 62.90M | 62.87M | 62.64M | 59.91M |
| Average Diluted Shares Outstanding | 63.07M | 62.90M | 62.87M | 62.64M | 59.91M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
